Therefore, the CD16bright NK cell subtype can effectively attack cancer cells by engaging their Fc receptor (CD16) to bind the Fc portion of the mediator antibody that recognizes tumor-associated antigens [90]. The gene discussed is FCGR3A; the disease is cancer.